Clinical trial of intrathecal administration of 5-fluoro-2'-deoxyuridine for treatment of meningeal dissemination of malignant tumors

Journal of Neuro-Oncology

Volumn 45, Issue 2, 1999, Pages 175-183

  Nakagawa, Hidemitsu ^a   Yamada, Masanobu ^a   Maeda, Nobuhiko ^a   Iwatsuki, Koichi ^a   Hirayama, Azuma ^a   Ikenaka, Kazuhiro ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b NATIONAL INSTITUTES OF NATURAL SCIENCES   (Japan)

Author keywords

FdUrd; Intrathecal chemotherapy; Meningeal dissemination

Indexed keywords

FLOXURIDINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; GLIOBLASTOMA; HUMAN; LUNG CANCER; LYMPHOMA; MALE; MALIGNANT TRANSFORMATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; FEMALE; FLOXURIDINE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SPINAL; LYMPHATIC METASTASIS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033498990     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006373905428     Document Type: Article

References (26)

1. Ongerboer de Visser BW, Somers R, Nooyen WH, Van Heerde P, Hart AAM, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565-1572, 1983
2. Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4: 68-73, 1986
3. Hitchins RN, Bell DR, Woods RL, Levi JA: A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5: 1655-1662, 1987
4. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumor: experience with 90 patients. Cancer 49: 759-772, 1982
5. Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 38: 696-699, 1981
6. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR: Treatment for meningeal carcinomatosis in breast cancer. Cancer 49: 219-222, 1982
7. Shapiron WR, Posner JB, Ushio Y, Chernik NL, Young DF: Treatment of meningeal neoplasms. Cancer Treat Rep 61: 733-743, 1977
8. Nakagawa H, Murasawa A, Kubo S, Nakajima S, Nakajima Y, Izumoto S, Hayakawa T: Diagnosis and treatment of patients with meningeal carcinomatosis. J Neuro-Oncol 13: 81-89, 1992
9. Trump DL, Grossman SA, Thompson G, Murray K, Wharam M: Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 66: 1549-1551, 1982
10. Birnie GD, Kroeger H, Heidelberger C: Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2′-deoxyuridine and related compounds by nucleoside phosphorylase. Biochemistry 2: 566-572, 1963
11. Parker WB, Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharmac Ther 48: 381-395, 1990
12. Koenig H, Patel A: Biochemical basis for fluorouracil neurotoxicity. Arch Neurol 23: 155-160, 1970
13. Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T: Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and α-fluoro-β-alanine. Acta Neuropathol 81: 66-73, 1990
14. Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K: In vitro study on intrathecal use of 5-fluoro- 2′-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors. J Neuro-Oncol 37:115-121, 1998
15. Nakagawa H, Yamada M, Fukushima M, Ikenaka K: Intrathecal 5-fluoro-2′-deoxyuridine (FdUrd) for the treatment of solid tumor neoplastic meningitis: an in vivo study. Cancer Chemother Pharmac 43: 247-256, 1998
16. Roosa RA, Bradley TD, Law LW, Herzenberg LA: Characterization of resistance to amethopterin, 8-azaguanine and several fluorinated pyrimidines in the murine lymphocytic neoplasm, P388. J Cell Comp Physiolo 60: 109-126, 1962
17. Kanzawa F, Hoshi A, Kuretani K: Differences between 5-fluoro-2′-deoxyuridine and 5-fluorouridine in their cytotoxic effect on growth of murine lymphoma L5178Y cells in in vivo and in vitro systems. Europ J Cancer 16: 1087-1092, 1980
18. Bosch L, Harbers E, Heidelberger C: Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res 18: 335-343, 1958
19. Condon B, Patterson J, Wyper D, Hadley D, Grant R, Teasdale G, Rowan J: Use of magnetic resonance imaging to measure intracranial cerebrospinal fluid volume. Lancet 1: 1355-1358, 1986
20. Teasdale GM, Grant R, Condon J, Patterson J, Lawrence A, Hadley DM, Wyper D: Intracranial CSF volumes: natural variations and physiological changes measured by MRI. Acta Neurochir 42 (Suppl): 230- 235, 1988
21. Pizzo PA, Poplack DG, Bleyer WA: Neurotoxicities of current leukemia therapy. Am J Pediat Hematol/Oncol 1: 127-140, 1979
22. Mott MG, Stevenson P, Wood CB: Methotrexate meningitis. Lancet 2: 656, 1972
23. Gagliano R, Costani J: Paraplegia following intrathecal methotrexate: report of a case and review of the literature. Cancer 37: 1663-1668, 1976
24. Price RA, Jamieson PA: The central nervous system in childhood leukemia.II. Subacute leukoencephalopathy. Cancer 35:306-318, 1975
25. Aur RJA, Hustu HO, Verzosa MS, Wood A, Simone JV: Comparison of two methods of preventing central nervous system leukemia. Blood 42: 349-357, 1973
26. Noell WK, Magoss MS, Cohen LH, Holland JF, Walters GC: Cerebral effects of folic acid, pyrimidines, amino acids and their antimetabolites. Electroencephalog Clin Neurophysiol 12: 238, 1960